

**A retrospective, descriptive study of neonates with Subaponeurotic Haemorrhage  
admitted in a public hospital in South Africa.**

**Delight Nyiko Baloyi**

0601018E

Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital  
and School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand  
Johannesburg South Africa

A research report Submitted to the School of Clinical Medicine Faculty of Health Sciences,  
University of The Witwatersrand, Johannesburg, in partial fulfillment of the requirements for  
the degree of Master of Medicine in branch of Paediatrics 2022

## DECLARATION

I Delight Nyiko Baloyi declare that this research report is my own, unaided work. It is being submitted for the Degree of Master of Medicine in the Branch of Paediatrics at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at any other University.

---

(Signature of Candidate)

11 day of November 2022

## **DEDICATION**

To my mother  
Tsakani Sophie Makhuvele  
and my daughter  
Vuako Andziso Baloyi  
for the love and faith in me.

## **Abstract**

### **Background**

Subaponeurotic haemorrhage (SAH) is an uncommon but potentially lethal birth injury. It is associated with instrumental delivery especially vacuum extraction. At risk infants should be monitored for the development of hypovolaemic shock which is associated with mortality.

### **Objective**

To determine the incidence, risk factors, management and outcome in neonates with SAH in a tertiary public hospital setting.

### **Methods**

This was a retrospective, descriptive study of neonates diagnosed with SAH admitted to the neonatal unit at Chris Hani Baragwanath Academic Hospital (CHBAH) between 1 January 2016 and 31 December 2017. Maternal and neonatal demographic data, risk factors, management and outcomes to discharge were collected from the REDCap (Research Electronic Data Capture) neonatal database and hospital records. Statistical analysis was conducted using Statistica (version 14.0).

### **Results**

The incidence was 3.5 per1000 live births. One hundred and seventy-eight neonates with SAH had data for analysis, 73.6% were male. The mode of delivery included, vacuum assisted (74, 41.6%), forceps (4, 2.25) and caesarean section after failed vacuum (9, 5%). Maternal risk factors included being primigravid (125, 70.2%) and prolonged second stage of labour (74, 75.5%). The most common comorbidities were jaundice (61, 34%) and hypoxic ischaemic encephalopathy (36, 20%). There was a decrease in head circumference ( $p=0.026$ ), post treatment with fresh frozen plasma. Eleven neonates (6.2%) required a blood transfusion, 34(19.1%) required phototherapy and 3 (1.7%) developed hypovolaemic shock requiring inotropic support and demised.

### **Conclusion**

The incidence of SAH was higher than previously reported. All neonates were treated with fresh frozen plasma irrespective of their severity and the overall mortality was low. Prompt recognition and treatment of SAH is associated with improved outcomes.

## **ACKNOWLEDGEMENT**

Prof Kebashni Thandrayen for her assistance with statistical analysis.

**TABLE OF CONTENTS**

COVER..... i  
DECLARATION..... ii

DEDICATION.....	iii
ABSTRACT.....	iv
ACKNOWLEDGEMENT.....	v
TABLE OF CONTENTS.....	vi
LIST OF TABLES AND FIGURES.....	vii
ABBREVIATIONS.....	viii

**PUBLICATION SUBMISSIBLE FORMATTED RESEARCH REPORT**

SAJCH Author Guidelines.....	1
Cover page.....	2
Introduction .....	3
Study Methods and Materials .....	4
Results.....	6
Discussion.....	7
Limitations .....	8
Conclusion.....	9
Acknowledgements.....	10
References.....	11
Figures.....	13
Tables.....	15
Appendix A: Protocol.....	18
Appendix B: Data collection sheet.....	30
Appendix C: Turn-It-In report.....	31
Appendix D: Ethics clearance certificate post protocol.....	33
Appendix E: Application letter for Title change.....	34
Appendix F: Ethics clearance certificate, tittle changed.....	35

**List of Figures and Tables**

Figure 1. Sample size: Flow Diagram of Neonates with SAH at CHBAH

Figure 2. Co- morbid Conditions of Neonates Admitted with SAH

Table 1. Maternal Characteristics

Table 2. Neonatal Characteristics of neonates with SAH

Table 3. Serial Head Circumference measurements at different time intervals

Table 4. Laboratory Results of Neonates admitted with SAH

## Abbreviations

aEEG	Amplitude <b>Integrated</b> Electroencephalogram
CHBAH	Chris Hani Baragwanath Academic hospital
CPD	Cephalopelvic Disproportion
DIC	Disseminated Intravascular Coagulopathy
FFP	Fresh Frozen Plasma
FBC	Full Blood Count
HC	Head Circumference
HDN	Haemorrhagic Disease of Newborn
HREC	Human Research Ethics Committee
HIE	Hypoxic Ischemic Encephalopathy
INR	International Normalized Ratio
IQR	Interquartile Ranges
IDM	Infant of Diabetic Mom
LGA	Large for Gestational Age
LBW	Low Birth weight
MAC	Medical Advisory Committee
MAS	Meconium Aspiration Syndrome
MOU	Midwife Obstetrics Units
NVD	Normal Vaginal Delivery
NICU	Neonatal Intensive Care
NNJ	Neonatal Jaundice
PTT	Phototherapy
PVL	Periventricular Leukomalacia
REDCap	Research Electronic Data Capture
RDS	Respiratory Distress Syndrome
RH Neg	Rhesus Negative
SBR	Serum Bilirubin
SAH	Subaponeurotic Haemorrhage
SGH	Subgaleal Haemorrhage



SD	Standard Deviation
TTN	Transient Tachypnoea of the Newborn
WCC	White Cell Count

1 AUTHOR GUIDELINES FOR SOUTH AFRICAN JOURNAL OF CHILD  
2 HEALTH (SAJCH)

3 The cover letter should contain the qualifications, full affiliation (department, school/faculty,  
4 institution, city, country) and contact details of ALL authors must be provided in the  
5 manuscript and in the online submission process. The article should be written in UK English  
6 including spelling, in Microsoft Word or RTF document format. Text must be 1.5 line  
7 spaced, in 12-point Times New Roman font, and contain no unnecessary formatting (such as  
8 text in boxes). Pages and lines should be numbered consecutively. Abbreviations should be  
9 spelt out when first used and thereafter used consistently

10 **Main Submission**

11 Research articles describe the background, methods, results and conclusions of an original  
12 research study. The article should contain the following sections: introduction, methods,  
13 results, discussion and conclusion, and should include a structured abstract

14 **The introduction** should be concise – no more than three paragraphs – on the background to  
15 the research question, and must include references to other relevant published studies that  
16 clearly lay out the rationale for conducting the study

17 **Study Methods** should be described in as much detail as possible so that others would be  
18 able to replicate the study should they need to.

19 **Results** should describe the study sample as well as the findings from the study itself

20 **Discussion** section will explain interpretation of findings, which should consider primary  
21 outcomes first before any secondary or tertiary findings or post-hoc analyses.

22 **The conclusion** should briefly summarise the main message of the paper and provide  
23 recommendations for further study.

24 **Tables: Tables** should be constructed carefully and simply for intelligible data  
25 representation.

26 *Structured abstract*

- 27 • This should be no more than 250 words, with the following recommended headings:  
28 ○ **Background:** why the study is being done and how it relates to other  
29 published work.  
30 ○ **Objectives:** what the study intends to find out  
31 ○ **Methods:** must include study design, number of participants, description of  
32 the intervention, primary and secondary outcomes, any specific analyses that  
33 were done on the data.  
34 ○ **Results:** first sentence must be brief population and sample description;  
35 outline the results according to the methods described. Primary outcomes must  
36 be described first, even if they are not the most significant findings of the  
37 study.  
38 ○ **Conclusion:** must be supported by the data, include recommendations for  
39 further study/actions. Do not include any references in the abstracts.

40 SUBMISSABLE FORMATTED RESEARCH REPORT

41

42 **A descriptive, retrospective study of neonates with Subaponeurotic Haemorrhage**  
43 **admitted in a public hospital in South Africa**

44

45 Delight Baloyi<sup>1</sup>, Alison van Kwawegen<sup>1</sup>, Firdose Lambey Nakwa<sup>1\*</sup>

46

47 <sup>1</sup>Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital  
48 and School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand.

49

50 **Correspondence:**

51 Delight Nyiko Baloyi

52 [0601018E@students.wits.ac.za](mailto:0601018E@students.wits.ac.za)

53

54 Chris Hani Baragwanath Academic Hospital

55 Department of Paediatrics and Child Health

56 16 Chris Hani Road

57 Diepkloof

58 PO Bertsham

59 2013

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75 **Introduction**

76

77 Subgaleal haemorrhage also referred to as subaponeurotic haemorrhage (SAH) is an  
78 uncommon but potentially lethal birth injury in new-borns. <sup>(1-4)</sup> It was first to described in  
79 1819 by Naegele, when he distinguished it from a cephalhaematoma. <sup>(5)</sup> SAH is an  
80 accumulation of blood in the subaponeurotic space between the epicranial aponeurosis of the  
81 scalp and the periosteum of the bone. The subgaleal space is a potential space that is  
82 estimated to accommodate up to 260 mls of blood. It extends anteriorly to the orbital margins  
83 and posteriorly to nuchal ridge and laterally to the temporal fascia. <sup>(3)</sup> Bleeding occurs when  
84 there is rupture of the emissary veins between the scalp and the meningeal veins and dural  
85 venous sinuses. <sup>(6)</sup> In term neonates where the circulating blood volume is 82-86 ml/kg, loss of  
86 blood up to 260 mls can result in hypovolaemic shock. <sup>(7)</sup> This condition can present as a  
87 spectrum from asymptomatic bleeding to a massive haemorrhage leading to hypovolaemic  
88 shock. <sup>(8)</sup> SAH should be differentiated from other head swellings such as cephalhaematoma  
89 or caput succedaneum. A cephalhaematoma develops due to an accumulation of blood  
90 between the periosteum and skull and is limited by the sutures, while caput succedaneum is  
91 oedema in subcutaneous tissue of the skull. <sup>(9)</sup> Diagnosis of SAH is based on history and  
92 clinical examination. Clinically, there is a diffuse, gravity dependent scalp swelling which  
93 crosses skull sutures and can also track to eyelids or displace the ear. <sup>(10)</sup> Regular observation  
94 for ongoing blood loss, is recommended in at risk infants. Measurements of the head  
95 circumference should be monitored hourly for the first 6-8 hours of life as an increase of 1cm  
96 is associated with blood loss in the subgaleal space of up to 260ml, a change in colour or  
97 displacement of ears will also indicate ongoing blood loss. <sup>(3)</sup> Vital signs, perfusion and blood  
98 pressure should be monitored to identify hypovolaemic shock.

99

100 The incidence is estimated to be 0.5-3 per 1000 live births which increases to 7.6/1000 live  
101 births for those with vacuum assisted deliveries. <sup>(11,12)</sup> Risk factors for the development of  
102 SAH include primigravid women, prolonged second stage of labour and instrumental  
103 delivery; particularly vacuum delivery. The use of a vacuum is as high as 64-89% in cases  
104 with SAH. <sup>(2,4,13-15)</sup> and there is a higher risk in cases of failed vacuum extraction, difficult  
105 extraction with repeated attempts and placement of the vacuum cup. <sup>(15)</sup> There has been an  
106 associated male predominance in neonates with SAH. SAH can be classified as mild,  
107 moderate or severe based on an increase in head circumference (HC), jaundice and

108 hypovolaemia in previously established criteria. <sup>(2)</sup> Severe SAH is defined as an increase in  
109 HC > 3cm, jaundice requiring an exchange transfusion or hypovolaemia requiring blood  
110 products and/or inotropic support. <sup>(15,16)</sup> Management includes vitamin K administration,  
111 normal saline as a plasma expander, fresh frozen plasma (FFP), blood or cryoprecipitate in  
112 cases of a coagulopathy. <sup>(17)</sup>

113

114 Reported mortality is 12-15% usually due to massive blood loss presenting with  
115 hypovolaemic shock, often in the setting of uncorrected coagulopathy. Poor outcome has  
116 been associated with neonates that had underlying hypotension, anaemia, coagulopathy and  
117 metabolic acidosis. <sup>(4,15)</sup> Severe birth asphyxia is a contributing factor to mortality in  
118 neonates with SAH. <sup>(14)</sup> Some studies have reported on long term neurological outcomes with  
119 some neonates developing spastic or hypotonic cerebral palsy and epilepsy. These outcomes  
120 are linked to the underlying co-morbid conditions. <sup>(15)</sup> SAH continues to be a concern to  
121 paediatricians and midwives because of the associated morbidity and mortality. SAH in  
122 majority of cases can be prevented by providing education and training in instrumental  
123 delivery especially in the use of the vacuum application. Monitoring of at risk neonates is  
124 essential to reduce the incidence of SAH and its associated complications. <sup>(18)</sup> In neonates  
125 early identification and prompt treatment results in a good prognosis with no long-term  
126 consequences. <sup>(16)</sup>

127

128 This study aimed to identify the incidence, maternal and neonatal characteristics, risk factors,  
129 co-morbidities, management and outcome in neonates with SAH in a tertiary public hospital  
130 setting.

131

132

### 133 **Materials and Methods**

134 This study was a retrospective, descriptive study of all neonates with subaponeurotic  
135 haemorrhage admitted to Chris Hani Baragwanath Academic Hospital (CHBAH) neonatal  
136 unit between 01 January 2016 to the 31 December 2017. CHBAH is a public tertiary hospital  
137 in Soweto, Johannesburg, South Africa. The surrounding midwife obstetric units (MOUs), as  
138 well as the district and regional hospitals refer high risk maternal deliveries to CHBAH or

139 neonates post-delivery who are assessed to require tertiary care.

140

141 All infants admitted with a diagnosis of (SAH) during the study period were included.  
142 Neonates diagnosed with SAH were identified from the computerized REDCap (research  
143 electronic data capture) neonatal database. The medical records of all neonates with a diagnosis  
144 of SAH were retrieved and data extracted. Data was collected on maternal and neonatal  
145 demographics, comorbid diagnosis, management and complications and outcomes to  
146 discharge.

147

148

### 149 **Data Analysis**

150 Data was entered into a Microsoft Excel database and exported into Statistica (version 14.0)  
151 for data analysis. Categorical variables were reported as numbers and percentages.

152 Continuous variables that were normally distributed were reported as means and standard  
153 deviations (SD) continuous variables that were not normally distributed were reported as  
154 medians and interquartile ranges (IQR). A p – value of < 0.05 was considered significant.

155

156

### 157 **Ethics Statement**

158

159 The study was approved by the Human Research Ethics Committee (HREC) of the  
160 University of the Witwatersrand (M180323). Approval to conduct the study was received  
161 from the hospital Medical Advisory Committee (MAC), paediatric departmental and neonatal  
162 divisional heads. This was a retrospective study thus parental consent was waived.

163

### 164 **Results**

165

166 A total of 55 965 live births were recorded during the study period, 39 794 (71%) at CHBAH  
167 and 16 171 (28.9%) from the district. (Figure 1). Sixteen percent (9141) of the neonates were  
168 admitted to the neonatal unit. A total of 198 neonates were diagnosed with SAH during the  
169 study period, giving an incidence of 3.5 per 1000 live births. Twenty files were not located  
170 thus the study cohort was 178 (1.94%). Most of the neonates in the study cohort, were inborn  
171 172 (96.6%) and survived to discharge n=175 (98.3%).

172

173 Maternal characteristics are presented in Table 1. Most of the mothers 125 (70.2%) who  
174 delivered neonates with SAH were primigravid. Fifty- five percent of mothers (98/178) had  
175 pregnancy complications, with prolonged second stage (75.5%) being the commonest  
176 complication. Seventy percent (125/178) of neonates were born vaginally, of these 74  
177 (59.2%) had an assisted vaginal delivery with a vacuum device. Nine of the 41 (22%)  
178 neonates that were delivered via cesarean section had had failed a vacuum delivery.

179

180 Neonatal characteristics are presented in Table 2. The median gestational age was 39 weeks  
181 (IQR 38 – 40 weeks), with a male predominance (73.6%). Majority had a normal birth  
182 weight (84.3%), with 16 (9.0%) being large for gestational age (LGA). The median 5-minute  
183 Apgar score was 9 (IQR 8-10). Three neonates were admitted to the intensive care unit while  
184 175 (98,3%) were admitted to the high care unit. The comorbidities of neonates diagnosed  
185 and admitted with SAH are presented in Figure 2. The most common comorbid diagnosis was  
186 jaundice 61 (34%) followed by hypoxic ischaemic encephalopathy (HIE) in 36 (20%)  
187 neonates, which was graded according to the modified Sarnat and Sarnat classification.<sup>(19)</sup>

188

### 189 **Head Circumference Measurements**

190 The diagnosis of SAH was made clinically, to assess severity serial measurements of head  
191 circumference were taken (Table 3). All 178 (100%) neonates had a head circumference  
192 measurement at birth. At 6 hours post-delivery, of the 168 (94%) neonates who had a head  
193 circumference measurement, a mean increase of 1cm ( $SD\pm 2.7$ ) was observed which was  
194 significant  $p=0.007$ . All 178 neonates in the study were treated with fresh frozen plasma  
195 (FFP) and vitamin K intravenously. Post management with FFP; the mean head  
196 circumference was 35.6 cm ( $SD\pm 1.4$ ) showing a significant decrease ( $p=0.026$ ). There were  
197 seventeen (9.5%) neonates who had an increase in head circumference and had a repeat dose  
198 of vitamin K and FFP.

199

### 200 **Imaging**

201 Thirty-one (17%) neonates had a cranial sonar. The reported abnormal findings were slit- like  
202 ventricles denoting cerebral oedema 15 (11.8%), increased brain echogenicity in 2 (1.1%)  
203 and periventricular leukomalacia (PVL) in 2 (1.1%) neonates.

204

### 205 **Laboratory studies**

206 Of the 152 (85%) neonates that had a full blood count (FBC) drawn the median haemoglobin  
207 was 16.1g/dL (IQR 14.5-17.4). The median white cell count (WCC) and platelets were 15.6  
208  $\times 10^9/L$  (IQR 12.2-18.7) and 199  $\times 10^9/L$  (IQR 157-245) respectively. All the neonates had a  
209 serum bilirubin drawn within 24 hours with a median bilirubin of 232 $\mu\text{mol/L}$  (IQR190-290).  
210 The median international normalized ratio (INR) in 26 neonates (15%) was 1.0 (IQR 1.0-1.1).

211 Table 4

212

### 213 **Morbidity and outcomes**

214 Three neonates with severe SAH and hypovolaemic shock required ventilation and inotropic  
215 support. Jaundice was diagnosed in 61 (65%) neonates and a third required phototherapy, no  
216 neonate had an exchange transfusion performed. Eleven of the twelve neonates diagnosed  
217 with anemia required a blood transfusion. Thirteen (7.3%) neonates had clinical seizures  
218 which were confirmed on amplitude electroencephalogram (aEEG), these neonates were  
219 treated with phenobarbitone and phenytoin.

220 The median length of stay was 3 (IQR 2-6) days. Neonates with jaundice had a longer length  
221 of stay. Three neonates demised giving a mortality of 1.7% and 175 (98,3%) of neonates  
222 were discharged home. Mortality was reported in neonates with lower APGAR scores and a  
223 diagnosis of HIE.

224

### 225 **Discussion**

226 This was a retrospective descriptive study at Chris Hani Baragwanath Academic Hospital  
227 (CHBAH) which reviewed 178 neonates with SAH, the largest cohort in the literature over a  
228 2-year period. Our incidence of 3.5 per1000 live births was higher than that of previous  
229 studies<sup>(2,3)</sup>; this could be because CHBAH is a referral center for high-risk pregnancies but  
230 may also reflect long waiting periods for emergency caesarian sections due to the limitations



231 of a busy tertiary hospital in a low resourced environment. Maternal factors such as  
232 primigravidity, and prolonged second stage, were found to be risk factors for the  
233 development for SAH, this is similar to other studies.<sup>(20)</sup>

234 In this study, 41.6 % of neonates with SAH were delivered using a vacuum while a further  
235 22.0% required a caesarean section after a failed vacuum attempt, in keeping with studies  
236 where vacuum delivery and the risk of developing SAH is as high as 210 per 1000 infants.<sup>(3)</sup>  
237 An increasing use of vacuum extraction to assist births has resulted in the increase of the  
238 prevalence of SAH in the high income countries (HIC) due to increased use of the forceps.<sup>(21)</sup>  
239 The authors postulate that the vacuum extractors are easier to apply and cause less maternal  
240 soft tissue trauma.<sup>(21)</sup> Our study found a relative male predominance of neonates with SAH  
241 in keeping with other studies.<sup>(4,17,20)</sup>

242

243 Monitoring of an at risk neonate at 1,6 and 24 hours in an intensive care setting was  
244 associated with the lowest mortality.<sup>(20)</sup> Colditz et al recommended that neonates at risk of  
245 SAH should be monitored at birth, 1 and 4 hours post-delivery and if hypotension or shock  
246 develops, then neonates are treated more aggressively with normal saline, packed red cell  
247 transfusions and intubation with inotropic support.<sup>(1)</sup> In our setting, monitoring was at birth,  
248 6 hours post treatment and prior to discharge. Head circumference measurements are used to  
249 estimate blood loss in neonates with SAH or risk factors for SAH.<sup>(3)</sup> All neonates with a  
250 diagnosis of SAH receive fresh frozen plasma as per our protocol and this was associated  
251 with a decrease in subsequent head circumference measurements.

252

253 Hypoxic ischemic encephalopathy (HIE) was the second most common co-morbid diagnosis  
254 in our study. HIE can be associated with haemodynamic instability, shock, DIC  
255 (disseminated intravascular coagulopathy) and parenchymal haemorrhage. In a study by Boo  
256 et al 15% of neonates with SAH had underlying birth asphyxia, and El-Dib et al reported  
257 23% of neonates with SAH had neonatal encephalopathy.<sup>(10,13)</sup> Underlying HIE has been  
258 associated with poor outcome as is the case in this study where the 3 neonates that demised  
259 had lower Apgar scores and a diagnosis of HIE.<sup>(17)</sup>

260

261 Subaponeurotic hemorrhage is diagnosed clinically, imaging is rarely recommended to  
262 diagnose or classify SAH. <sup>(6)</sup> In the CHBAH study cranial sonar was indicated in the neonates  
263 with underlying comorbidities such as HIE, findings included, cerebral oedema and  
264 periventricular leukomalacia. Chang HY et al had similar ultrasound findings in 13 neonates.  
265 <sup>(4)</sup>

266 Coagulopathy has been reported to be associated with SAH. <sup>(2)</sup> Haemostatic disturbances  
267 have been documented in severe forms of SAH. <sup>(21)</sup> In the current study there was no  
268 evidence of a coagulopathy but the numbers were too small to attribute this as a causal effect  
269 of SAH.

270 Swanson et al only treated neonates with severe SAH, or underlying coagulopathy with FFP  
271 and vitamin K, in our setting all neonates with SAH were treated with FFP and vitamin K. <sup>(17)</sup>  
272 There are no randomized control trials in LMIC and HIC to compare expectant management  
273 to routine management with FFP and vitamin K administration in neonates with SAH.  
274 Monitoring in our setting can be challenging with staff to patient ratios that are suboptimal.  
275 The rationale for using FFP is the assumption that the neonate has a coagulopathy. Data to  
276 support routine use of FFP in all neonates with SAH is limited.

277

278 Mortality in neonates with SAH is associated with severe blood loss, anemia, hypovolemic  
279 shock and metabolic acidosis, with mortality as high as 15 %. <sup>(15,16)</sup> The mortality in the  
280 current study was 1.7 %, which was relatively low in comparison to some settings and may  
281 reflect our practice of treating all infants diagnosed with SAH with FFP. Neonates that  
282 demised during the study period had a similar profile as in other settings such as hypovolemic  
283 shock and underlying HIE.

284

## 285 **Limitations**

286 This is a retrospective study with missing data for some neonates as 20 files could not be  
287 retrieved. Monitoring of head circumference and documentation thereof was not consistently  
288 recorded in all neonates.

289

## 290 **Conclusion**

291 Symptomatic SAH is a rare neonatal emergency with potentially serious complications,  
292 leading to morbidity and mortality. SAH has a good prognosis provided there are no  
293 associated co-morbidities. To reduce mortality early identification of at-risk neonates and  
294 constant monitoring for potential complications is imperative. Aggressive management of  
295 shock is important to reduce mortality. Long-term follow up of neonates with SAH and  
296 comorbidities would be a future recommendation.

297

298

### 299 **Acknowledgements**

300 Thank you to Professor K. Thandrayen for statistical assistance.

301

### 302 **Conflicts of Interest**

303 The authors have no conflicts of interests.

304

### 305 **Authorship**

306 DNB, AvK, FLN conceptualized the study. DNB wrote the first draft. DNB, AvK and FLN  
307 reviewed and edited the manuscript. All authors approved the submission of the final  
308 manuscript.

309

310

311

312

313

314

315

316

317

318

319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354

**References:**

1. Colditz MJ, Lai MM, Cartwright DW, Colditz PB. Subgaleal haemorrhage in the newborn: A call for early diagnosis and aggressive management: Subgaleal haemorrhage in the newborn. *J Paediatr Child Health* (2015) 51:140–146. doi: 10.1111/jpc.12698
2. Chadwick L, Pemberton P, Kurinczuk J. Neonatal subgaleal haematoma: Associated risk factors, complications and outcome. *J Paediatr Child Health* (1996) 32:228–232. doi: 10.1111/j.1440-1754.1996.tb01559.x
3. Plauché WC. Subgaleal Hematoma: A Complication of Instrumental Delivery. *JAMA*. 1980;244(14):1597-8.
4. Chang H-Y, Peng C-C, Kao H-A, Hsu C-H, Hung H-Y, Chang J-H. Neonatal subgaleal hemorrhage: Clinical presentation, treatment, and predictors of poor prognosis. *Pediatr Int* (2007) 49:903–907. doi: 10.1111/j.1442-200X.2007.02482.x
5. Kicklighter S, Wolfe D, Perciaccante J. Subgaleal hemorrhage with dural tear and parietal-lobe herniation in association with a vacuum extraction. *Journal of Perinatology*. 2007;27(12):797-9.
6. Davis DJ. Neonatal subgaleal hemorrhage: diagnosis and management. *Canadian Medical Association Journal*. 2001;164(10):1452-3.
7. Amar AP, Aryan HE, Meltzer HS, Levy ML. Neonatal Subgaleal Hematoma Causing Brain Compression: Report of Two Cases and Review of the Literature. *Neurosurgery*. 2003;52(6):1470-4.
8. Reid J. Neonatal Subgaleal Hemorrhage. *Neonatal Netw* (2007) 26:219–227. doi: 10.1891/0730-0832.26.4.219
9. Liu LY, Antaya RJ. Neonatal Subgaleal Hematoma from Trauma During Vaginal Delivery without Instrument Use. *Pediatric Dermatology*. 2017;34(1):e40-e1.
10. El-Dib M, Parziale MP, Johnson L, Benson CB, Grant PE, Robinson J, Volpe JJ, Inder T. Encephalopathy in neonates with subgaleal hemorrhage is a key predictor of outcome. *Pediatr Res* (2019) 86:234–241. doi: 10.1038/s41390-019-0400-1

- 355 11. Fakih HM. Spontaneous Neonatal Subgaleal Hematomas after Caesarian Section.  
356 Journal of Case Reports. 2015;4(2):359-62.
- 357 12. Chia C-C. Neonatal coagulopathy presents as unusual and severe subgaleal hematomas  
358 after vacuum delivery. *Taiwanese journal of obstetrics & gynecology*.47(4):435-7.
- 359 13. Boo NY. Subaponeurotic haemorrhage in Malaysian neonates. *Singapore Med J*.  
360 1990;31(3):207-10.
- 361 14. Ng PC, Siu YK, Lewindon PJ. Subaponeurotic haemorrhage in the 1990s: a 3-year  
362 surveillance. *Acta Paediatr*. 1995;84(9):1065-9.
- 363 15. Lee SJ, Kim JK, Kim SJ. The clinical characteristics and prognosis of subgaleal  
364 hemorrhage in newborn. *Korean Journal of Pediatrics*. 2018;61(12):387-91.
- 365 16. Kilani RA, Wetmore J. Neonatal subgaleal hematoma: presentation and outcome-  
366 radiological findings and factors associated with mortality. *American journal of*  
367 *perinatology*. 2006;23(01):041-8.
- 368 17. Swanson AE, Veldman A, Wallace EM, Malhotra A. Subgaleal hemorrhage: risk factors  
369 and outcomes: Subgaleal hemorrhage. *Acta Obstet Gynecol Scand* (2012) 91:260–263.  
370 doi: 10.1111/j.1600-0412.2011.01300.x
- 371 18. NASSERI F, BADAEE Z. NEONATAL SUBGALEAL HEMORRHAGE “A FATAL  
372 COMPLICATION OF VACUUM EXTRACTION DELIVERY.” *Iran J Pediatr* (2007)  
373 17:297–301. <https://www.sid.ir/en/Journal/ViewPaper.aspx?ID=88138>
- 374 19. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and  
375 electroencephalographic study. *Arch Neurol* (1976) 33:696–705. doi:  
376 10.1001/archneur.1976.00500100030012. PMID: 987769.
- 377 20. Boo N-Y. Risk factors associated with subaponeurotic haemorrhage in full-term infants  
378 exposed to vacuum extraction. *BJOG : an international journal of obstetrics and*  
379 *gynaecology*.112(11):1516-21.
- 380 21. Uchil D, Arulkumaran S. Neonatal subgaleal hemorrhage and its relationship to delivery  
381 by vacuum extraction. *Obstet Gynecol Surv*. 2003;58(10):687-93.

382

383

384

385

386

387


388

389

390

391

392



393

Figure 1: Flow Diagram of Neonates with SAH at CHBAH

394


395

396

397

398

399



400

401 **Figure 2: Co morbid Conditions of Neonates Admitted with SAH**

402 HIE- Hypoxic Ischemic Encephalopathy, HDN- Haemorrhagic Disease of Newborn IDM -Infant of Diabetic  
 403 Mom, LBW -Low Birth Weight, MAS - Meconium Aspiration Syndrome, NNJ -Neonatal Jaundice, RH neg-  
 404 Rhesus Negative, RDS- Respiratory Distress Syndrome TTN- Transient Tachypnoea of Newborn

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419 **Table 1: Maternal Characteristics**

<b>Maternal Characteristics</b>	<b>Number (%) n=178</b>
<b>Parity</b> Primigravidae Multiparous	125 (70.2) 53 (29.8)
<b>Pregnancy complications</b> n=98 Prolonged Second Stage CPD	74 (75.5) 24 (24.5)
<b>Mode of Delivery</b> Spontaneous NVD NVD assisted Vacuum Forceps Caesarian Section Forceps Failed vacuum	47 (26.4) 74 (41.6) 4 (2.2) 41 (23.0) 3 (1.7) 9 (5.1)

420 NVD normal vaginal delivery, CPD cephalopelvic disproportion

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436



437 **Table 2: Infant Characteristics**

<b>Infant Characteristics</b>	<b>Number (%)</b>
Place of Birth Inborn Outborn	172 (96.6) 6 (3.4)
Gestational age*	39 (38-40)
Birthweight <2500g ≥2500g – 4000g >4000g	12 (6.7) 150 (84.3) 16 (9.0)
Apgar score <7* 1 minute 5 minute	7 (6-9) 9 (8-10)
Gender Female Male	47 (26.4) 131 (73.6)
Admission ward NICU High Care	3 (1.7) 175 (98.3)
Complications Anaemia(<10g/dl) NNJ requiring PTT NNJ not requiring PTT Hypovolemic shock Seizures	12 (6.7) 34 (19.1) 27 (15.1) 3 (1.7) 13 (7.3)
Length of stay (days)*	3 (2-6)
Outcome Discharged Died	175 (98.3) 3 (1.7)

438 \*Median and interquartile ranges (IQR), NICU neonatal intensive care unit, PTT phototherapy,  
 439 and NNJ neonatal jaundice

440  
 441  
 442  
 443  
 444  
 445

446 **Table 3: Serial Head Circumference measurements at different time intervals**

Time intervals of head circumference measurements	N (%)	Mean (SD) (cm)	p value
At birth	178 (100)	36 ( $\pm$ 2.1)	
At 6 hours	168 (94)	37 ( $\pm$ 2.7)	0.007
Post FFP	123 (69)	35.6 ( $\pm$ 1.4)	0.026
At 24 hours	56 (31)	35 ( $\pm$ 1.21)	0.039
At discharge	33 (19)	35 ( $\pm$ 0.89)	

447 SD – Standard deviation, FFP – Fresh Frozen Plasma

448

449 **Table 4: Laboratory Results of Neonates admitted with SAH**

Variable	N (%)	Median (IQR)
White cell count X10 <sup>9</sup> /L	144 (81)	15.6 (12.2 – 18.7)
Haemoglobin (Hb) g/dl	152 (85)	16.1 (14.5 – 17.4)
Platelet X10 <sup>9</sup> /L	143 (80)	199 (157 - 245)
SBR $\mu$ mol/l	178 (100)	232 (190 - 290)
INR	26 (15)	1.0 (1.0 – 1.1)

450 SBR – serum bilirubin, INR – international normalized ratio

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467 **APPENDICES**

468

469 **Appendix A Protocol**

470

471 A CLINICAL PROFILE, MANAGEMENT AND OUTCOME OF INFANTS WITH A  
472 SUBAPONEUROTIC HAEMORRHAGE IN CHRIS HANI BARAGWANATH  
473 ACADEMIC HOSPITAL

474

475 DR DELIGHT NYIKO BALOYI

476

477 MMED PAEDITRICS

478 MP 0729272

479 STAFF NO A0053802

480 STUDENT NO: 0601018E

481

482 SUPERVISORS

483 Dr F Nakwa

484 Neonatologist, Head of Department Neonates Unit Chris Hani Baragwanath Academic  
485 Hospital

486 Dr A Van Kwawegen

487 Neonatologist Chris Hani Baragwanath Academic Hospital

488

489	Outline
490	
491	1. Introduction
492	2. Literature review
493	3. Aim of study
494	4. Study objectives
495	5. Sample size
496	6. Methods
497	7. Data analysis
498	8. Ethics
499	9. Risk and benefits
500	10. Timeline
501	11. Funding
502	12. Limitations
503	13. References
504	14. Data sheet

505 STUDY TOPIC

506 A CLINICAL PROFILE, MANAGEMENT AND OUTCOME OF INFANTS WITH A  
507 SUBAPONEUROTIC HAEMORRHAGE IN CHRIS HANI BARAGWANATH  
508 ACADEMIC HOSPITAL

509

510

511 1. INTRODUCTION

512 Subgaleal haemorrhage is an uncommon but potentially lethal condition found in newborns.  
513 In 1819 Naegele was first to describe the lesion whilst differentiating true sub periosteal  
514 heamatoma from false heamatoma. Subgaleal haemorrhage is also known as subaponeurotic  
515 haemorrhage (SAH).<sup>(1)</sup> This condition can present as a spectrum from asymptomatic  
516 bleeding to a massive haemorrhage leading to hypovolemic shock. It is often underreported  
517 and may be misdiagnosed.<sup>(2)</sup> This condition can result in bleeding under the aponeurosis  
518 which if not recognized can compromise the affected neonate. SAH continues to be a  
519 concern to pediatricians and midwives because of the associated mortality and morbidity.  
520 Prompt recognition and appropriate management improves the outcome of the affected  
521 neonates.<sup>(3)</sup>

522

523 2. LITERATURE REVIEW

524 Subaponeurotic haemorrhage (SAH) occurs because of birth trauma due to the shearing  
525 forces on the scalp during delivery. This results in the accumulation of blood between the  
526 skull periosteum and galeal aponeurotica.<sup>(4)</sup> Anatomically the scalp is made of 5 layers' skin,  
527 connective tissue, galeal aponeurotica, loose connective tissue and periosteum. SAH occurs  
528 when the emissary veins in subgaleal space rupture. Rupturing of these veins can occur after  
529 twisting or torsion of scalp. This is then followed by blood accumulating between the  
530 epicranial aponeurosis and the periosteum. This potential space can hold up to 260mls of  
531 blood leading to volume depletion. A term neonates total blood volume is about 80mls/kg<sup>(5)</sup>.

532 In a study by McQuivey it was suggested that the potential space of a newborn during a bleed  
533 can accommodate 50 to 80% of the blood volume which can be catastrophic.<sup>(6)</sup> The severity  
534 of a SAH was also assessed by looking at head circumference, jaundice as well as  
535 hypovolemia. These parameters were used to determine if the SAH was mild, moderate or  
536 severe.<sup>(7)</sup> Mild SAH is determined by increase of head circumference without jaundice or  
537 hypovolemia. On the other spectrum moderate is determine by increase of head  
538 circumference by at least 1-3cm with use of plasma expander. Severe SAH is characterized  
539 by increase in head circumference >3cm and use of blood and plasma expander this may also  
540 lead to one or more blood transfusion.

541 Due to the enclosed blood loss, this condition is probably underestimated, in a study by  
542 Chadwick the incidence was noted to be 0.2- 0.3 per live birth.<sup>(2)</sup> Another study by Reid  
543 quoted the incidence in the developing countries such as Africa as 0.8 per 1000 live births.  
544 Scotland a developed country had a higher incidence of 1.02 per 1000 live births this may  
545 reflect better methods of data collection.<sup>(8)</sup> The highest incidence of 3 per 1000 births was  
546 noted by Cebremarium in Ethiopia<sup>(9)</sup>. The causes of SAH in this study was attributed to

547 difficult, traumatic deliveries and incorrect vacuum technique. In a public hospital in Cape  
548 Town studies showed an increase in SAH amongst the African (Black) population, related to  
549 traumatic deliveries especially in primigravida, as well as vacuum assisted vaginal deliveries.  
550 <sup>(10)</sup> The increase risk in the African population was also related to an increase incidence of  
551 haemorrhagic disease of newborns. <sup>(11)</sup> The incidence of SAH in spontaneous delivery were  
552 between 0.1 to 0.6 per 1000 vaginal deliveries <sup>(12-14)</sup>

553

554 The extraction of a neonate by ventouse was described first in 1705 by Dr Yonge. It  
555 continued gaining popularity by the 1950s following studies which were done in Sweden. By  
556 the 1970s it seems to have gained popularity compared to assisted forceps delivery in most  
557 European countries <sup>(15)</sup> Over the years with an increased use of the vacuum as a mode of  
558 delivery it has been associated with an increased number of patients with SAH. Whilst it is  
559 more likely associated with instrument\or assisted deliveries it can also occur in spontaneous  
560 deliveries. <sup>(6)</sup> Other risk factors include macrosomia, prolonged second stage of labour, fetal  
561 distress, primigravida, prematurity, shoulder dystocia, precipitous labour and neonates with  
562 congenital coagulopathy. <sup>(5,8,16)</sup>

563

564 In a Malaysian study by Boo et al the incidence of SAH was higher in neonates with weight  
565 greater than 4000g <sup>(16)</sup> .The larger infants had increased force against the maternal pelvis  
566 which did increase the risk of vascular stretching associated with an SAH. <sup>(17)</sup> In primiparous  
567 women due to increase of heavy perennial muscle stretching on the scalp, can lead to tears in  
568 the emissary vein <sup>(8)</sup> This muscle resistance is a factor for assisted deliveries such as vacuum  
569 mode of delivery in primigravida patients, is associated with prolonged second stage is  
570 associated with increase time of interstitial fluid accumulation which then had increased  
571 tissue vulnerability to injury in SAH. in the premature infants the risk was related to the  
572 factors leading to premature delivery.

573 In a study conducted in African neonates with SAH highlighted association of assisted  
574 delivery, weight greater than 3Kg, these infants had symptoms within 4 -48 hours of delivery  
575 and received a blood transfusion as part of their management . <sup>(11)</sup>.

576 Vacuum use was noted to be as high as 60 to 89% in cases with SAH. <sup>(18)</sup> The risk with  
577 vacuum use was noted to be higher with in cases of failed vacuum, difficult extraction  
578 (repeated attempts) as well as the placement of the vacuum. <sup>(1)</sup> Failed vacuum occurs when  
579 there is failure to deliver a baby within at least 15- 30 minutes, this must be with the correct  
580 application of the vacuum with at least 2- 3 pop offs or 3 sets of pulls. Doronjski et al also  
581 described a case of a neonate with hemophilia A who developed SAH as a first presentation.  
582 Coagulopathy has been described in neonates with SAH. Male infants had increased risk of  
583 developing SAH as compared to females as males had an higher risk of developing bleeding  
584 disorders. <sup>(19)</sup>

585

586 An SAH presents with a boggy, fluctuant mass under the scalp an increased head  
587 circumference <sup>(13)</sup> . It crosses suture lines, extends to involve the anterior neck and the  
588 superior orbital ridges. <sup>(20)</sup> The diagnosis can be made within the first 4 – 6 hours of life. It is a  
589 progressive injury; the skin may change to bluish – blackish bruising which can be seen in the

590 occipital and frontal areas. For these reasons it has been recommended that neonates with a  
591 difficult vacuum should be monitored for at least 8 hours. <sup>(21)</sup>

592

593 Infants with increased risk factors need to be monitored for signs of hypovolemic shock such  
594 as tachycardia, tachypnoea, acidosis and hypotension. <sup>(16)</sup> <sup>(1)</sup> once diagnosis of SAH has been  
595 made Serial head circumference measurements at least (at birth , an hour later , 6 hours and  
596 after 24 hours) <sup>(19)</sup> blood pressure and ongoing monitoring. Investigations in an infant with  
597 SAH include full blood count (FBC) and platelet count bilirubin levels as well as coagulation  
598 studies form part of monitoring and investigations. <sup>(16)</sup>

599 Imaging is not indicated as a method of investigation, Ultrasound a simple method used  
600 however does not give any information regarding the nature of the fluid. In patients with  
601 severe disease, a Computerized tomography (CT) scans of the skull showed low density  
602 enhancement in the region around the head. It was also useful to detect other associated  
603 injuries such as skull fractures. CT did reveal amount of extra osseous bleeding and extent of  
604 damage in the intracranial structures. <sup>(22)</sup> MRI was a better method in neonates with SAH, it  
605 confirmed the nature of the subgaleal fluid in comparison to other imaging modalities. <sup>(23)</sup>  
606 Imaging was at times indicated in cases with other comorbidities such as intraventricular  
607 haemorrhage (IVH), subarachnoid haemorrhage , periventricular leukomalacia and subdural  
608 haemorrhage<sup>(4)</sup> which when missed can lead to the rapid decompensation of a newborn with  
609 an SAH. Imaging is indicated in neonates with other comorbidities.

610

611 Boo et al described complications in patients with an SAH 32.7% developed anaemia 9.1%  
612 developed severe haemorrhage and shock requiring blood transfusion. 56.4 % of these  
613 patients had unconjugated hyperbilirubinemia and of the neonates with hyperbilirubinemia  
614 7% required an exchange transfusion. <sup>(19)</sup> Other complications described by Chang include  
615 seizures, impaired renal and liver function, and in severe cases disseminated intravascular  
616 coagulopathy(DIC) which is related to consumption of clotting factors. <sup>(13)</sup> Persistence of  
617 hypovolemic shock was mostly implicated in development of severe complications. A rare  
618 complication of infected SAH has been reported, this was seen in patients that had a  
619 traumatic scalp laceration <sup>(24)</sup> Lifelong complications include epilepsy, impaired auditory  
620 function and cerebral palsy. These are associated with comorbidities and or the complications  
621 associated with an SAH

622

623 There are no randomized control trials to compare management however the standard  
624 management recommended is the use of fresh frozen plasma (FFP) as well as Vitamin K. The  
625 transfusion of FFP has been regarded as a mode of treatment to correct DIC. <sup>(25)</sup> In cases  
626 where bleeding did not stop despite giving FFP, platelet transfusion was considered as a  
627 modality of treatment. Recombinant activated factor VII has been used to correct the  
628 coagulopathy in patients with increased risk of development of coagulopathy. Head wrapping  
629 has been suggested as a method of treatment. This is difficult to use <sup>(26)</sup> and contributes to  
630 an increased intracranial pressure. <sup>(27)</sup>

631 In other centers some neonates were managed in NICU, these included neonates with  
632 seizures, hypoxic ischemic encephalopathy (HIE) and respiratory distress. Patients with poor

633 outcomes were noted to have coagulopathy, impaired renal function, renal vein thrombosis  
634 and severe anaemia, hemoglobin less than 10g/dl. These patients were noted to have an  
635 increased length of hospital stay.<sup>(13)</sup>

636

637 A high index of suspicion needs to be maintained in patients with risk factors for SAH as  
638 well as treated to avoid morbidity and mortality. In a Taiwanese study with 41 neonates with  
639 SAH about 31% percent of patients had poor outcome, which included patients who  
640 (5,12,1%) died, (4,10%) had epilepsy, (1,2,4%) with renal vein thrombosis and (2,5%) had  
641 cerebral palsy. A delay in diagnosis, failure to recognize deterioration, and misdiagnosis have  
642 been noted to be contributing factors to mortality. Patients with the worst outcome required  
643 transfusion, ventilator support, NICU admission as well as prolonged hospital stay. Mortality  
644 attributed to volume loss, anaemia, coagulopathy and shock, multiple organ failure and  
645 severe encephalopathy was reported up to 22.8%.

646 In a previous study recorded mortality of about 11,8% out of 34 neonates with SAH, this was  
647 attributed to volume loss anaemia coagulopathy and shock.<sup>(28)</sup> intracranial haemorrhage,  
648 subarachnoid haemorrhage and skull fractures which are related to morbidities in neonates  
649 with SAH.<sup>(28)</sup> Monitoring of neonates after instrumental delivery has also been associated  
650 with increased earlier identification as well as appropriate treatment of this condition.<sup>(1)</sup>

651 In Chris Hani Baragwanath Academic Hospital (CHBAH) being one of the largest hospitals  
652 in Southern Africa. CHBAH is a tertiary/ quaternary center that accepts referrals from  
653 maternal obstetric units (MOUs), surrounding district and regional hospitals of mothers that  
654 require specialized care. There are 2 obstetric theatres with an average of 20000 deliveries a  
655 year. There are 4000 admissions to the neonatal unit with several term babies admitted. SAH  
656 is diagnosed in several term neonates admitted in the unit. This study will assist in  
657 quantifying the burden of neonates presenting with risk factors as well as management  
658 practices and outcomes of SAH in the neonatal unit. The study will also highlight the impact  
659 SAH has on mostly term neonates focusing on complications clinicians can avoid as well as  
660 treat promptly

661

### 662 3. AIM OF STUDY

663 To determine the clinical profile, management and outcomes of neonates admitted with SAH  
664 to the Chris Hani Baragwanath neonatal unit. Additionally, to explore the management  
665 strategies used in Chris Hani Baragwanath Academic Hospital and identify better ways to  
666 monitor these neonates to reduce mortality and morbidity.

667

### 668 4. STUDY OBJECTIVES

- 669 1. To describe the incidence of neonates with SAH in Chris Hani Baragwanath  
670 Academic Hospital
- 671 2. To describe demographics of neonates with subaponeurotic haemorrhage at Chris  
672 Hani Baragwanath Academic Hospital



- 673 3. To identify common risk factors in neonates with SAH such as instrumental delivery,  
674 prolonged second stage of labour, CPD etc.
- 675 4. To describe morbidity defined as anaemia, jaundice, exchange transfusions, shock and  
676 length of stay in neonatal unit
- 677 5. To describe treatment strategies of neonates admitted with SAH
- 678 6. To estimate number of newborns with SAH who developed complicated anaemia  
679 requiring transfusion as well as those with severe hypovolemic shock needing NICU  
680 admission
- 681 7. To describe outcomes of neonates in association to the identified risk factors

682

## 683 5. SAMPLE SIZE

684 The study will include all neonates admitted with SAH to the Chris Hani Baragwanath  
685 Academic Hospital neonatal unit between period of January 2016 to December 2017. An  
686 estimate of +/- 150 patients with SAH have been identified in the neonatal redcap data base  
687 system.

688

## 689 6. METHODS

690 This will be a descriptive retrospective cohort study. This study will include all babies with  
691 SAH admitted to the unit between January 2016 until December 2017. Patient information  
692 will be obtained from computerized neonatal database of neonates admitted to Chris Hani  
693 Baragwanath Academic Hospital Neonatal Unit. Redcap (research electronic data capture)  
694 system will be used to access data from Chris Hani Baragwanath academic Hospital database.  
695 The files of patients with an SAH will be retrieved and included to the study. The  
696 demographics of the patients will be collected as per data sheet (Appendix A)

697

## 698 7. DATA ANALYSIS

699 The statistics will be mainly descriptive. Data will be entered into an Excel spreadsheet.  
700 Thereafter, the data will be analyzed utilizing Statistica (version 14.0). Categorical variables  
701 will be reported as numbers and percentages. Continuous variables will be reported as means  
702 and standard deviations if not normally distributed, if not normally distributed the data will  
703 be represented as medians and interquartile ranges. Comparative statistics, student –t tests or  
704 Mann-Whitney U tests will be used for continuous variables and Chi squares and Fischer  
705 exact tests will be used for categorical values to compare groups 1) those who survived to the  
706 ones who demised 2) those with different treatment modalities e.g. treated with vitamin K  
707 and FFP to those treated with Vitamin K, FFP and blood transfusion 3) those who were  
708 ventilated compared to those who were not ventilated. A p value <0.05 will be considered as  
709 significant.

710

711

712 8. ETHICS

713 Consent will be obtained from the national department of health to obtain approval to conduct  
714 the study. Ethics approval will be requested from the Human Research Ethics committee  
715 from the University of Witwatersrand. The data obtained from the neonatal unit's files shall  
716 be handled with utmost security, will remain a product of the University of Witwatersrand as  
717 well as Chris Hani Baragwanath Academic Hospital (CHBAH). Patient identifiers will be  
718 kept separately from patient's demographics. The two data sources will be linked by a study  
719 number.

720

721 9. RISK AND BENEFITS

- 722 1. This study will serve to highlight the burden of SAH in our unit and assist in  
723 identifying knowledge to clinicians in the unit to be aware of the morbidity as well as  
724 mortality of neonates with SAH. The information obtained will assist in identifying  
725 infants with higher risk to complicate. No risk to any of the participants as most data  
726 will be obtained from Chris Hani Baragwanath Academic Hospital neonatal records.

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746 10. TIMELINE:

747

Year	2017			2017				2018				2019				
Activity	June	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept
Literature Review	Black			Dark Blue												
Preparation of protocol					Dark Blue	Dark Blue	Dark Blue									
Submission to Ethics								Blue	Blue	Light Blue	Dark Blue					
Submission of protocol								Blue	Blue	Light Blue	Dark Blue					
Data collection												Red	Red	Red	Red	Red
Data analysis									Purple	Purple	Purple	Purple				
Write up of research report																

748

Year	2019							2020-2021	2022				
Activity	June	Jul	Aug	Sep	Oct	Nov	Dec	Mar-Dec Covid	Jan	Feb	Mar	Apr	May
Literature Review								Red					
Preparation of protocol								Red					
Submission to Ethics								Red					
Submission of protocol								Red					
Data collection					Red	Red	Red	Red					
Data analysis	Purple	Purple	Purple	Purple	Purple	Purple	Purple	Red					
Write up of research report	Green	Green						Red	Green	Green	Green	Green	Green

749

750

751

752 11. FUNDING

753 The costs involved in the study will be borne by the researcher

754

755 12. LIMITATIONS

756 This will be a retrospective study and information is dependent on the practitioner attending  
757 patient and completing the medical records accurately.

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783 13. REFERENCES

- 784 1.Colditz MJ, Lai MM, Cartwright DW, Colditz PB. Subgaleal haemorrhage in the newborn:  
785 A call for early diagnosis and aggressive management. *Journal of paediatrics and child*  
786 *health*. 2015;51(2):140-6.
- 787 2.Christensen R, Baer V, Henry E. Neonatal subgaleal hemorrhage in a multihospital  
788 healthcare system: prevalence, associations, and outcomes. *EJ Neonatol Res*. 2011;1:4-11.
- 789 3.Hangai M, Kimura Y, Mori H, Yasui K, Tsuchida S, Takahashi N. Computetomography  
790 findings of ongoing subgaleal hemorrhage. *Pediatrics international : official journal of the*  
791 *Japan Pediatric Society*. 2014;56(4):623-6.
- 792 4.Swanson AE, Veldman A, Wallace EM, Malhotra A. Subgaleal hemorrhage: risk factors  
793 and outcomes. *Acta obstetricia et gynecologica Scandinavica*. 2012;91(2):260-3.
- 794 5.Schierholz E, Walker SR. Responding to traumatic birth: subgaleal hemorrhage,  
795 assessment, and management during transport. *Advances in neonatal care : official journal of*  
796 *the National Association of Neonatal Nurses*. 2010;10(6):311-5.
- 797 6.Davis DJ. Neonatal subgaleal hemorrhage: diagnosis and management. *CMAJ : Canadian*  
798 *Medical Association journal = journal de l'Association medicale canadienne*.  
799 2001;164(10):1452-3.
- 800 7.Chadwick LM, Pemberton PJ, Kurinczuk JJ. Neonatal subgaleal haematoma: associated  
801 risk factors, complications and outcome. *Journal of paediatrics and child health*.  
802 1996;32(3):228-32.
- 803 8.Reid J. Neonatal subgaleal hemorrhage. *Neonatal network : NN*. 2007;26(4):219-27.
- 804 9.Gebremariam A. Subgaleal haemorrhage: risk factors and neurological and developmental  
805 outcome in survivors. *Annals of tropical paediatrics*. 1999;19(1):45-50.
- 806 10.A. Williams MF, Jacobs, M., amp, amp, Moosa. Subaponeurotic haemorrhage of the  
807 newborn. *South African Medical Journal*. 1977;52(5):176-8.
- 808 11.Robinson R, Rossiter MA. Massive subaponeurotic haemorrhage in babies of African  
809 origin. *Archives of disease in childhood*. 1968;43(232):684.
- 810 12.Plauche WC. Subgaleal hematoma. A complication of instrumental delivery. *Jama*.  
811 1980;244(14):1597-8.
- 812 13.Chang HY, Peng CC, Kao HA, Hsu CH, Hung HY, Chang JH. Neonatal subgaleal  
813 hemorrhage: clinical presentation, treatment, and predictors of poor prognosis. *Pediatrics*  
814 *international : official journal of the Japan Pediatric Society*. 2007;49(6):903-7.
- 815 14.Ng P, Siu Y, Lewindon P. Subaponeurotic haemorrhage in the 1990s: a 3-year  
816 surveillance. *Acta Paediatrica*. 1995;84(9):1065-9.
- 817 15.Ali UA, Norwitz ER. Vacuum-assisted vaginal delivery. *Reviews in Obstetrics and*  
818 *Gynecology*. 2009;2(1):5.
- 819 16.Uchil D, Arulkumaran S. Neonatal subgaleal hemorrhage and its relationship to delivery  
820 by vacuum extraction. *Obstetrical & gynecological survey*. 2003;58(10):687-93.

821 17.Ross MG, Fresquez M, El-Haddad MA. Impact of FDA advisory on reported vacuum-  
822 assisted delivery and morbidity. *The Journal of maternal-fetal medicine*. 2000;9(6):321-6.

823 18.C Ng P, Siu YK, Lewindon P. Subaponeurotic haemorrhage in the 1990s: A 3-year  
824 surveillance1995. 1065-9 p.

825 19.Boo N. Subaponeurotic haemorrhage in Malaysian neonates. *Singapore Med J*.  
826 1990;31(3):207-10.

827 20.Cavlovich FE. Subgaleal hemorrhage in the neonate. *Journal of obstetric, gynecologic,  
828 and neonatal nursing : JOGNN*. 1995;24(5):397-404.

829 21.Chia CC, Huang SC. Neonatal coagulopathy presents as unusual and severe subgaleal  
830 hematomas after vacuum delivery. *Taiwanese journal of obstetrics & gynecology*.  
831 2008;47(4):435-7.

832 22.Govaert P, Vanhaesebrouck P, De Praeter C, Moens K, Leroy J. Vacuum extraction, bone  
833 injury and neonatal subgaleal bleeding. *European journal of pediatrics*. 1992;151(7):532-5.

834 23.King S, Boothroyd A. Cranial trauma following birth in term infants. *The British journal  
835 of radiology*. 1998;71(842):233-8.

836 24.Chang HY, Cheng KS, Liu YP, Hung HF, Fu HW. Neonatal infected subgaleal  
837 hematoma: an unusual complication of early-onset E. coli sepsis. *Pediatrics and neonatology*.  
838 2015;56(2):126-8.

839 25.Modanlou H, Hutson S, Merritt AT. Early Blood Transfusion and Resolution of  
840 Disseminated Intravascular Coagulation Associated with Massive Subgaleal Hemorrhage.  
841 *Neonatal network : NN*. 2016;35(1):37-41.

842 26.Amar AP, Aryan HE, Meltzer HS, Levy ML. Neonatal subgaleal hematoma causing brain  
843 compression: report of two cases and review of the literature. *Neurosurgery*.  
844 2003;52(6):1470-4; discussion 4.

845 27.Vacca A. Birth by vacuum extraction: neonatal outcome. *Journal of paediatrics and child  
846 health*. 1996;32(3):204-6.

847 28.Kilani RA, Wetmore J. Neonatal subgaleal hematoma: presentation and outcome--  
848 radiological findings and factors associated with mortality. *American journal of perinatology*.  
849 2006;23(1):41-8.

850

851

852

853

854

855

856

857

858 **Appendix B**

859

860 DATA SHEET: SAH

861 **1 Infant details**

862 Study No \_\_\_\_\_

863 Place of birth 1 CHBAH 2 Clinic 3 Home 4 Other Hosp

864 Place of Admission: TICU/ NICU.

865 Gestational Age: \_\_\_\_\_ Gender: M/F Birth Weight \_\_\_\_\_

866 APGARS: 1 min \_\_\_\_\_ 5 Min \_\_\_\_\_

867 Mode of delivery: NVD  Forceps  Vacuum , Number of attempts \_\_\_\_\_ C/section

868 **2. Maternal**

869 Primigravida: YES /NO

870 Prolonged second stage: YES /NO CPD: YES / NO

871 **3. MONITORING**

872 Head circumference: Increase \_\_\_\_\_ CM \_\_\_\_/Static \_\_\_\_\_ Decrease \_\_\_\_

873 Time of Head Circumference: birth \_\_\_\_ 6 hours \_\_\_\_\_, 24 Hours \_\_\_\_

874 Head Circumference post treatment \_\_\_\_/Discharge \_\_\_\_

875 **4. Investigation**

876 Bloods: FBC WCC \_\_\_\_ HB \_\_\_\_ Platelet \_\_\_\_\_ SBR: Total bilirubin YES/NO \_\_\_\_\_

877 INR/PTT \_\_\_\_\_

878 Urea and Electrolytes: NA \_\_, K \_\_, CL \_\_\_\_\_, Urea \_\_\_\_, Creatinine \_\_\_\_, HCO<sub>3</sub> \_\_\_\_\_

879 IMAGING YES/NO

880 IMAGING: ultrasound YES/NO CT scan YES/NO MRI YES/NO

881 Findings of imaging \_\_\_\_\_

882 **5. Management**

883 Ventilated Yes / no Indication for ventilation \_\_\_\_\_

884 Vitamin K \_\_\_\_\_ FFP \_\_\_\_\_, No of infusions \_\_\_\_\_, Packed red cells \_\_\_\_\_

885 Platelet transfusion \_\_\_\_\_ phototherapy \_\_\_\_\_ UREA AND ELECTROLYTES \_\_\_\_\_

886 **6. Morbidity**

887 Jaundice  Anaemia  Hypovolemic shock  Hypotension  Inotropes  Neurological

888 Impairment

889

890 **7. Diagnosis**

891 HIE  MAS  IVH  Intracranial bleeds

892

893 **7. Outcome**

894 Discharged Home YES/NO

895 Died YES /NO

896

897

898

899

900 **Appendix C Turn-It-In Report**

00100697:MMED\_Delight\_2022\_17\_August\_for\_Turn-It-  
\_In.docx

ORIGINALITY REPORT

<b>10%</b>	<b>8%</b>	<b>11%</b>	<b>2%</b>
SIMILARITY INDEX	INTERNET SOURCES	PUBLICATIONS	STUDENT PAPERS

PRIMARY SOURCES

<b>1</b>	LM CHADWICK. "Neonatal subgaleal haematoma: Associated risk factors, complications and outcome", Journal of Paediatrics and Child Health, 6/1996 Publication	<b>2%</b>
<b>2</b>	Bmcpediatr.Biomedcentral.Com Internet Source	<b>1%</b>
<b>3</b>	sajch.org.za Internet Source	<b>1%</b>
<b>4</b>	"Neonatology", Springer Science and Business Media LLC, 2018 Publication	<b>1%</b>
<b>5</b>	www.medrxiv.org Internet Source	<b>1%</b>
<b>6</b>	docksci.com Internet Source	<b>1%</b>
<b>7</b>	Mohamed El-Dib, Melanie P Parziale, Lise Johnson, Carol B. Benson et al. "Encephalopathy in neonates with subgaleal	<b>1%</b>

901

902



## hemorrhage is a key predictor of outcome", Pediatric Research, 2019

Publication

---

<b>8</b>	<a href="http://www.seslhd.health.nsw.gov.au">www.seslhd.health.nsw.gov.au</a> Internet Source	1 %
<b>9</b>	<a href="http://silo.pub">silo.pub</a> Internet Source	1 %
<b>10</b>	<a href="http://worldwidescience.org">worldwidescience.org</a> Internet Source	1 %
<b>11</b>	Keeling s Fetal and Neonatal Pathology, 2015. Publication	1 %

---

Exclude quotes  On

Exclude matches  < 1%

Exclude bibliography  On

903

904

905

906

907

908

909

910

911

912

913

914

915

916



R14/49 Dr ND Baloyi

**HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)  
CLEARANCE CERTIFICATE NO. M180323**

**NAME:** Dr ND Baloyi  
**(Principal Investigator)**  
**DEPARTMENT:** School of Clinical Medicine  
Department of Paediatrics and Child Health  
Neonatal Unit  
Chris Hani Baragwanath Academic Hospital

**PROJECT TITLE:** A clinical profile, management and outcome of neonates with a subaponeurotic haemorrhage in Chris Hani Baragwanath Academic Hospital Neonatal Unit

**DATE CONSIDERED:** 06/04/2018

**DECISION:** Approved unconditionally

**CONDITIONS:**

**SUPERVISOR:** Dr F. Nakwa and Dr A. Van Kwawegen

**APPROVED BY:**   
\_\_\_\_\_  
Professor CB Penny, Chairperson, HREC (Medical)

**DATE OF APPROVAL:** 17/04/2018

This clearance certificate is valid for 5 years from date of approval. Extension may be applied for.

**DECLARATION OF INVESTIGATORS**

To be completed in duplicate and ONE COPY returned to the Research Office Secretary on 3rd floor, Philip V Tobias Building, Parktown, University of the Witwatersrand, Johannesburg.  
I/We fully understand the conditions under which I am/we are authorised to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated from the research protocol as approved, I/We undertake to resubmit to the Committee. I agree to submit a yearly progress report. The date for annual re-certification will be one year after the date of convened meeting where the study was initially reviewed. In this case, the study was initially reviewed in March and will therefore be due in the month of March each year. Unreported changes to the application may invalidate the clearance given by the HREC (Medical).

Principal Investigator Signature \_\_\_\_\_

Date \_\_\_\_\_

PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES

918  
919  
920  
921



Private Bag 3 Wits, 2050  
Fax: 027117172119  
Tel: 02711 7172076

Reference: Mrs Sandra Benn  
E-mail: [sandra.benn@wits.ac.za](mailto:sandra.benn@wits.ac.za)

29 August 2022  
Person No: 0601018E  
TAA

Miss ND Baloyi  
P O Box 8213  
Elandsfontein  
1406  
South Africa

Dear Miss Nyiko Baloyi

**Master of Medicine in Paediatrics: Change of title of research**

I am pleased to inform you that the following change in the title of your Research Report for the degree of **Master of Medicine in Paediatrics** has been approved:

From: **A clinical profile, management and outcome of infants with subaponeurotic haemorrhage in Chris Hani Baragwanath Academic Hospital**

To: **A retrospective, descriptive study of neonates with subaponeurotic haemorrhage admitted in a public tertiary hospital in South Africa**

Yours sincerely

A handwritten signature in black ink, appearing to read "S Benn".

Mrs Sandra Benn  
Faculty Registrar  
Faculty of Health Sciences

## Appendix F: Ethics Clearance Certificate, Title Changed

UNIVERSITY OF THE  
WITWATERSRAND  
JOHANNESBURG



R14/48 Dr ND Baloyi

### HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) CLEARANCE CERTIFICATE NO. M180323

**NAME:** Dr ND Baloyi  
**(Principal Investigator)**  
**DEPARTMENT:** School of Clinical Medicine  
Department of Paediatrics and Child Health  
Neonatal Unit  
Chris Hani Baragwanath Academic Hospital


**PROJECT TITLE:** A retrospective, descriptive study of neonates with subaponeurotic haemorrhage admitted in a public tertiary hospital in South Africa

**DATE CONSIDERED:** 06/04/2018

**DECISION:** Approved unconditionally

**CONDITIONS:**

**SUPERVISOR:** Dr F. Nakwa and Dr A. Van Kwawegen

**APPROVED BY:**   
Dr CB Peary, Chairperson, HREC (Medical)

**DATE OF APPROVAL:** 17/04/2018 (Initial approval) ; 30/08/2022 (Change of title)

This clearance certificate is valid for 5 years from date of approval. Extension may be applied for.

#### DECLARATION OF INVESTIGATORS

To be completed in duplicate and ONE COPY returned to the Research Office Secretary on the Third Floor, Faculty of Health Sciences, Philip Tobias Building, 29 Princess of Wales Terrace, Parktown, 2193, University of the Witwatersrand. I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated, from the research protocol as approved, I/we undertake to resubmit the application to the Committee. I agree to submit a yearly progress report. The date for annual re-certification will be one year after the date of convened meeting where the study was initially reviewed. In this case, the study was initially reviewed in March and will therefore be due in the month of March each year. Unreported changes to the application may invalidate the clearance given by the HREC (Medical).

\_\_\_\_\_  
Principal Investigator Signature

\_\_\_\_\_  
Date

PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES